Thérapie génique BS01 pour l'atrophie géographique dans les patients atteints de DMLA sèche

This study aims to explore the safety and effectiveness of a new treatment called BS01 for patients with a condition known as geographic atrophy (GA), which is linked to dry age-related macular degeneration (AMD). Dry AMD is a common eye disease that can cause vision loss in older adults, and GA is an advanced form of this condition. The study is important because there are currently limited treatment options available for this type of vision loss. By testing this new approach, researchers hope to find a way to slow down or improve the condition, offering hope for better management of GA. Participants in this study receive an injection of the treatment directly into the eye, known as an intravitreal injection. The study is carried out in two parts: the first part tests different doses to find the most appropriate one, while the second part focuses on expanding the study to more patients using the selected dose. Some participants will receive a sham injection, which means they undergo a procedure without the active treatment, to help compare results. Researchers will assess the safety of the treatment and its ability to improve or stabilize vision, providing valuable information on potential risks and benefits.